88 Results

People

  1. Rampal
    Rampal
  2. Levine
    Levine
  3. Horwitz
    Horwitz
  4. Tamari
    Tamari
  5. Bowman
    Bowman
  6. Kleppe
    Kleppe
  7. Koche
    Koche
  8. Abdel-Wahab
    Abdel-Wahab
  9. Cordner
    Cordner
  10. Dunbar
    Dunbar

Groups

  1. Department of Medicine (73)
  2. Center for Hematologic Malignancies (65)
  3. Hematologic Malignancies, Division of (65)
  4. Adult Leukemia (45)
  5. GSK Faculty (25)
  6. Human Oncology and Pathogenesis Program (20)
  7. Executive Committee, Center for Hematologic Malignancies (19)
  8. Sloan Kettering Institute Postdocs (16)
  9. MSK Grad Students (13)
  10. Center for Molecular Imaging and Biotechnology (CMIB) (11)
  1. "ruxolitinib"
Formats
  1. Journal Article (62)
  2. Review (15)
  3. Meeting Abstract (5)
  4. Editorial (3)
  5. Research Letter (2)
  6. Miscellaneous (1)
Groups
  1. Department of Medicine (73)
  2. Center for Hematologic Malignancies (65)
  3. Hematologic Malignancies, Division of (65)
  4. Adult Leukemia (45)
  5. GSK Faculty (25)
  6. Human Oncology and Pathogenesis Program (20)

More Groups

People
  1. Raajit Rampal (34)
  2. Ross Levine (17)
  3. Roni Tamari (8)
  4. Steven Horwitz (6)
  5. Maria Kleppe (4)
  6. Richard Koche (4)

More People

Years
  1. 2025 (10)
  2. 2024 (16)
  3. 2023 (10)
  4. 2022 (7)
  5. 2021 (5)
  6. 2020 (8)

More Years

Publications
  1. Blood (7)
  2. Clinical Lymphoma, Myeloma and Leukemia (6)
  3. Blood Advances (4)
  4. Bone Marrow Transplantation (4)
  5. Current Hematologic Malignancy Reports (3)
  6. Haematologica (3)

More Publications

Publishers
  1. Elsevier Inc. (15)
  2. Nature Publishing Group (12)
  3. American Society of Hematology (11)
  4. Springer (6)
  5. American Association for Cancer Research (4)
  6. American Society of Clinical Oncology (3)

More Publishers

Results (88)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Ruxolitinib therapy followed by reduced-intensity conditioning for hematopoietic cell transplantation for myelofibrosis: Myeloproliferative Disorders Research Consortium 114 Study
    Journal Article

    Gupta, V.; Kosiorek, H. E.; Mead, A.; Klisovic, R. B.; Galvin, J. P.; Berenzon, D.; Yacoub, A.; Viswabandya, A.; Mesa, R. A.; Goldberg, J.; more...
    Biology of Blood and Marrow Transplantation (2019)

    Fulltext@MSK | Save
  • Leukemic transformation of myeloproliferative neoplasms: Therapeutic and genomic considerations
    Journal Article

    Li, B.; Mascarenhas, J. O.; Rampal, R. K.
    Current Hematologic Malignancy Reports (2018)

    Fulltext@MSK | Save
  • Dual targeting of oncogenic activation and inflammatory signaling increases therapeutic efficacy in myeloproliferative neoplasms
    Journal Article

    Kleppe, M.; Koche, R.; Zou, L.; van Galen, P.; Hill, C. E.; Dong, L.; De Groote, S.; Papalexi, E.; Hanasoge Somasundara, A. V.; Cordner, K.; more...
    Cancer Cell (2018)

    Fulltext@MSK | Save
  • Inhibition of mTORC1/C2 signaling improves anti-leukemia efficacy of JAK/STAT blockade in CRLF2 rearranged and/or JAK driven Philadelphia chromosome-like acute B-cell lymphoblastic leukemia
    Journal Article

    Zhang, Q.; Shi, C.; Han, L.; Jain, N.; Roberts, K. G.; Ma, H.; Cai, T.; Cavazos, A.; Tabe, Y.; Jacamo, R. O.; more...
    Oncotarget (2018)

    Fulltext@MSK | Save
  • JAK2/IDH-mutant–driven myeloproliferative neoplasm is sensitive to combined targeted inhibition
    Journal Article

    McKenney, A. S.; Lau, A. N.; Hanasoge Somasundara, A. V.; Spitzer, B.; Intlekofer, A. M.; Ahn, J.; Shank, K.; Rapaport, F. T.; Patel, M. A.; Papalexi, E.; more...
    Journal of Clinical Investigation (2018)

    Fulltext@MSK | Save
  • Mediator kinase phosphorylation of STAT1 S727 promotes growth of neoplasms with JAK-STAT activation
    Journal Article

    Nitulescu, I. I.; Meyer, S. C.; Wen, Q. J.; Crispino, J. D.; Lemieux, M. E.; Levine, R. L.; Pelish, H. E.; Shair, M. D.
    EBioMedicine (2017)

    Fulltext@MSK | Save
  • Pharmaceutical marketing for rare diseases: Regulating drug company promotion in an era of unprecedented advertisement
    Journal Article

    Mailankody, S.; Prasad, V.
    JAMA - Journal of the American Medical Association (2017)

    Fulltext@MSK | Save
  • A Phase 1/2 trial of ruxolitinib and erlotinib in patients with EGFR-mutant lung adenocarcinomas with acquired resistance to erlotinib
    Journal Article

    Yu, H. A.; Perez, L.; Chang, Q.; Gao, S. P.; Kris, M. G.; Riely, G. J.; Bromberg, J.
    Journal of Thoracic Oncology (2017)

    Fulltext@MSK | Save
  • Janus kinase inhibition lessens inflammation and ameliorates disease in murine models of hemophagocytic lymphohistiocytosis
    Journal Article

    Das, R.; Guan, P.; Sprague, L.; Verbist, K.; Tedrick, P.; An, Q. A.; Cheng, C.; Kurachi, M.; Levine, R.; Wherry, E. J.; more...
    Blood (2016)

    Fulltext@MSK | Save
  • Outcomes of allogeneic hematopoietic cell transplantation in patients with myelofibrosis with prior exposure to Janus kinase 1/2 inhibitors
    Journal Article

    Shanavas, M.; Popat, U.; Michaelis, L. C.; Fauble, V.; McLornan, D.; Klisovic, R.; Mascarenhas, J.; Tamari, R.; Arcasoy, M. O.; Davies, J.; more...
    Biology of Blood and Marrow Transplantation (2016)

    Fulltext@MSK | Save